CD93 and acute myeloid leukemia: Collectively, genetic backgrounds and respective phenotypes are in parts linked in AML [105] and may be therapeutically exploitable in some cases (e.g., CD93 targeting in MLLr AML [82] or CD26 in FLT3 ITD AML [25]).